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linical and Genetic Issues
n Familial Dilated Cardiomyopathy
mily L. Burkett, MS, CGC, Ray E. Hershberger, MD, FACC
ortland, Oregon
Idiopathic dilated cardiomyopathy (IDC) is characterized by left ventricular dilatation and
systolic dysfunction after known causes have been excluded. Idiopathic dilated cardiomyop-
athy occurring in families, or familial dilated cardiomyopathy (FDC), may occur in 20% to
50% of IDC cases. Sixteen genes have been shown to cause autosomal dominant FDC, but
collectively may account for only a fraction of genetic causation; it is anticipated that
additional genes causative of FDC will be discovered. Familial dilated cardiomyopathy
demonstrates incomplete penetrance, variable expression, and significant locus and allelic
heterogeneity, making clinical and genetic diagnosis complex. Echocardiographic and
electrocardiographic screening of first-degree relatives of individuals with IDC and FDC is
indicated, as detection and treatment are possible before the onset of advanced symptomatic
disease. Genetic counseling for IDC and FDC is also indicated to assist with family
evaluations for genetic disease and with the uncertainty and anxiety surrounding the
significance of clinical and genetic evaluation. Genetic testing is not yet commonly available,
but its emergence will provide new opportunities for presymptomatic diagnosis. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.066Cardiol 2005;45:969–81) © 2005 by the American College of Cardiology Foundation
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rdiopathic dilated cardiomyopathy (IDC) is a diagnosis that
ontinues to puzzle many cardiovascular specialists. The
iagnosis of IDC is one of exclusion; that is, all obvious or
etectable causes should be excluded before its assignment.
et thoughtful clinicians recognize that some cause, albeit
nseen or undetected, underlies the myocardial dysfunction.
ultiple causes have been suggested and include previous
iral infections, excessive alcohol exposure, severe hyperten-
ion, and autoimmune or other phenomena.
An alternative cause, also unseen and difficult to detect, is
nderlying genetic disease. The clinical and genetic data to
upport genetic causation, and preliminary recommenda-
ions for cardiovascular specialists to deal with this disease,
re the focus of this review. That cardiovascular disease can
e caused by mutations in genes that encode for key proteins
mportant in cardiovascular biology has been elegantly
escribed for other myocardial diseases, most notably for
ypertrophic cardiomyopathy (HCM), now recognized
argely as a genetic disease of contractile proteins (1). Other
enetic cardiovascular diseases include the long QT syn-
rome (2), arrhythmogenic right ventricular dysplasia (3),
nd Marfan syndrome (4). Recent clinical studies have also
uggested that bicuspid aortic valve is heritable (5), and
trial fibrillation may be familial in 5% to 15% (6) to 30%
7) of cases.
Genetic disease also underlies a considerable proportion
f what has been previously understood to be IDC. The
linical and molecular genetic data gleaned from studies of
From the Division of Cardiology, Department of Medicine, Oregon Health and
cience University, Portland, Oregon. Dr. Hershberger is supported by an NIH
ward, RO1-HL58626.o
Manuscript received July 2, 2004; revised manuscript received September 16, 2004,
ccepted November 22, 2004.amilial dilated cardiomyopathy (FDC, defined as the pres-
nce of IDC in two or more family members) indicate that
ene mutations, largely single base changes in key autosomal
enes, cause FDC and IDC. The identity of the genes
nvolved, their mutation frequency, mechanisms of disease,
nd phenotype/genotype correlations are beginning to
merge.
DC CLINICAL AND FAMILY STUDIES
genetic basis for IDC was thought to be distinctly
ncommon until the mid-1980s. Familial transmission in
% to 2% of subjects with IDC had been postulated from
arlier scattered case reports (for earlier reviews, see refer-
nces 8–15). Before the widespread availability of echocar-
iography to screen family members, the research devoted
o hereditary cardiomyopathy had difficulty sorting hyper-
rophic from dilated cardiomyopathy (DCM). Other recent
verviews of FDC are available (16–23).
The recognition that DCMmay aggregate in families has
volved significantly since the early case reports (8,24–41)
Table 1). Based on family history, two initial studies in
982 and 1985 reported FDC rates of 2% and 6.5%
espectively (8,25) (Table 1). In 1988, a small prospective
chocardiographic-based study suggested a much higher
ate of 33% (27). That same year in children 2 years of
ge, the FDC rate was observed to be 25% (28). In 1992,
rospective echo screening of first-degree relatives in pa-
ients diagnosed with IDC estimated the rate of FDC at
0.3% (32). In this study, 315 relatives of the 59 index
atients with IDC underwent screening with echocardiog-
aphy, including coronary angiography in those 40 years
f age to exclude coronary artery disease. Idiopathic dilated
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Issues in Familial Dilated Cardiomyopathy April 5, 2005:969–81ardiomyopathy was found in 18 relatives (20.3% of the
ndex patients) by echocardiography, whereas only 5% had
een suspected of having familial disease based on family
istory alone. Of the 18 relatives, 12 were asymptomatic and
5 were given new diagnoses.
In 1997, a prospective study of 56 probands estimated the
definite” FDC rate at 25%, where “definite” was defined as
first-degree relative with a diagnosis of IDC, or both an
chocardiographic left ventricular end-diastolic dimension
2 standard deviations above the mean and an ejection
raction 50% (37). An additional 27% of probands had a
rst-degree relative with one of these two echocardiographic
riteria, or premature sudden death (unexplained 50 years
f age); these were categorized as “possible” FDC. The sum
f both “definite” and “possible” FDC rates was 52% (37).
Two reports (38,39), published simultaneously in 1998,
ndicated that FDC rates among patients with IDC ranged
rom 35% (38) to 48% if left ventricular enlargement (LVE)
as included as a clinical indicator of FDC (39) (Table 1).
n the former study (38), family history was obtained in 445
f 481 consecutive subjects (92.5%) with IDC. Dilated
ardiomyopathy was discovered in 65 subjects from 48 of
he 445 families (10.8%) as determined by full cardiac
valuation or at autopsy. Of the 65 subjects observed to have
CM during the study, 38 were newly identified by
rospective screening. In an additional 108 of the 445
amilies (24.2%), FDC was eventually diagnosed on the
asis of sudden cardiac death (75 families), heart failure
HF) (23 families), or abnormal echocardiography (10
amilies). In the remaining 289 families (65%), no evidence
f familial disease was observed. The latter study (39)
dentified 110 consecutive patients with documented IDC;
f these, 408 subjects from 89 different families (an average
f 4.6 members per family) agreed to undergo full clinical
creening. Forty-five of the relatives screened had LVE; 7 of
he 45 had DCM (LVE and decreased systolic function).
ith LVE included as early evidence of disease, the
revalence of FDC among index patients with IDC was
8% (39).
Clinical screening, regardless of family history, was of-
ered to 350 patients with IDC in Trieste, Italy, identified
etween 1991 and 1997 (40), and 281 family members from
Abbreviations and Acronyms
AD  autosomal dominant
CK  creatine kinase
CLIA  Clinical Laboratories Improvement Act
DCM  dilated cardiomyopathy
ECG  electrocardiography
FDC  familial dilated cardiomyopathy
HCM  hypertrophic cardiomyopathy
HF  heart failure
IDC  idiopathic dilated cardiomyopathy
LVE  left ventricular enlargement0 families were investigated based on their geographicroximity. Thirty-nine of the 60 families (65%) had familial
isease. When familial disease was compared to nonfamilial
isease, only a younger age of onset was predictive. The
nvestigators concluded that although FDC was frequent,
o particular clinical or morphologic features of individual
atients distinguished FDC from IDC, and thus family
creening was required to detect it.
DC DISEASE GENES AND CHROMOSOMAL LOCI
utosomal dominant (AD). Familial dilated cardiomyop-
thy has been reported most commonly (approximately
0%) with AD inheritance (40). The genetic and clinical
eterogeneity suggests causation by a single gene, with
ultiple other genetic and environmental factors altering its
xpressivity (40). To date mutations in 16 autosomal genes
42–66) have been suggested to be causative of FDC and
ave been categorized as FDC and FDC with conduction
ystem disease (Table 2). The former category has no
pecific or unique phenotypic features. The latter category
ncludes families with mutations in lamin A/C who fre-
uently present with sinoatrial and atrioventricular node
ysfunction, heart block commonly requiring pacemakers,
trial fibrillation, and other supraventricular arrhythmias;
ater DCM, ventricular arrhythmias, and death from sudden
ardiac death or pump failure are observed. Based on these
reliminary reports (Table 2), mutations in the lamin A/C
nd beta-myosin heavy chain genes may each be responsible
or 5% to 10% of FDC. However, these estimates have been
erived from patients and their families seen in specialist or
eferral clinics that may not be representative of overall
opulation frequencies. Actin (67–69) and desmin (69)
enes appear to be quite uncommon causes (1%) of IDC
nd FDC. Preliminary estimates of the frequencies of the
ther FDC genes are largely based upon the primary reports
Table 2), but appear to be less common causes of FDC
han the lamin A/C and beta-myosin heavy chain genes.
tudies designed to survey disease gene frequencies in larger
opulations will be required to clarify these issues.
-linked. X-linked FDC is reported to account for ap-
roximately 5% to 10% of FDC (Table 2) (38–40), usually
esulting from mutations in the dystrophin gene that have
een identified in several families displaying X-linked in-
eritance (70–78). In some cases, DCM has also been noted
o be the only or presenting feature in individuals who have
ecker muscular dystrophy or in female carriers (79,80).
urthermore, Becker muscular dystrophy and IDC have
een seen in the same family (81), suggesting that it may be
ifficult to draw conclusions about phenotype from geno-
ype. Individuals with X-linked FDC may have skeletal
uscle weakness, and whereas most have elevated creatine
inase (CK) levels, normal levels have been reported (40).
ystrophin mutations have also been identified in male
atients diagnosed with IDC, suggesting that this may be a
are cause of sporadic cases (20,82).
Mutations in the gene G4.5, which encodes the tafazzin
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April 5, 2005:969–81 Issues in Familial Dilated Cardiomyopathyamily of proteins, cause Barth syndrome (83) and neonatal
on-compaction of the left ventricular myocardium (84).
4.5 mutations have also been implicated as the cause of a
onsyndromic, lethal infantile form of X-linked FDC (85).
utosomal recessive. A mutation in cardiac troponin I has
een shown to cause recessive FDC in one family (86)
Table 2). Autosomal recessive inheritance is more common
mong certain ethnic groups and may be responsible for
ome cases of especially young (10 years) onset (87).
DC with skeletal muscle disease. Minor skeletal muscle
eakness has also been described in a few families with AD
DC (40,88), including two families with lamin mutations
60,61). Affected subjects may have elevated CK levels, but
alues have been noted to fluctuate from normal to overtly
bnormal over time.
itochondrial mutations. Mitochondrial point mutations
nd/or deletions have been reported in individuals with
DC (89–92) and FDC (93,94). However, many of these
utations are found in control subjects as well and may not
e the primary cause of the disease, but rather a cofactor in
ts development (40).
dditional chromosomal loci identified through linkage
nalysis. Autosomal dominant FDC has been linked to
even additional loci at which no disease genes have been
dentified. In four of these, cardiac dilatation has been the
rimary and presenting feature (95–98); in one of these
itral valve prolapse preceded the onset of cardiomyopathy
96) and in another sensorineural hearing loss was associated
97). The remaining three linkage reports describe DCM
ssociated with conduction system disease (88,99,100).
LINICAL GENETICS OF FDC
stablishing causality of DCM from gene mutations. One
f the most challenging issues in the investigation of genetic
auses of DCM is the establishment of causation from a
utation, which in the case of AD inheritance is usually a
ingle base missense or nonsense mutation. How is one
onvinced that the identified mutation actually causes
CM? The disease phenotype should segregate with the
utation in a large family containing members that have
oth normal and affected phenotypes. Ideally, these associ-
tions can be identified in multiple families. Other evidence
hat builds the case includes the absence of the mutation in
large control group, the occurrence of the disease gene in
conserved region, finding a de novo mutation, and a
lausible pathophysiologic role of the putative disease gene
n the development of DCM. Further evidence of DCM in
n animal model harboring the same mutation also
trengthens the case.
enetrance and disease expression. Penetrance is a mea-
ure of the percentage of individuals who carry a particular
ene mutation who are affected by the disorder. For exam-
le, for a disorder with 80% penetrance, of those who carry
he gene mutation 80% will manifest its effects. This is
eferred to as incomplete penetrance. Familial dilated car- aiomyopathy demonstrates incomplete age-dependent pen-
trance (for example, see accounts of lamin cardiomyopathy
40,59,62,63]) as well as variable expression. Among indi-
iduals carrying a particular gene mutation, there may be
ide variability in phenotypic effects and severity, both
ithin and between families. Families therefore often dem-
nstrate a wide range of mild to severe disease across all
enerations. Within the same family, the disease may range
rom subtle clinical symptoms and/or mild arrhythmias to
udden death or DCM leading to HF and/or cardiac
ransplantation. Therefore, it can be difficult to recognize
DC as a single genetic entity when investigating family
edigrees. This variability is crucial to convey in genetic
ounseling, as an adult with mild or nonpenetrant disease
emains at risk for having offspring with a more severe
henotype.
LINICAL SCREENING RECOMMENDATIONS FOR FDC
diopathic dilated cardiomyopathy can be divided into
resymptomatic and symptomatic stages. The symptomatic
resentation of IDC most commonly includes HF, arrhyth-
ia including sudden cardiac death, or thromboembolism.
ardiovascular evaluation for other reasons, such as routine
r prenatal exams, sports physical examinations, preopera-
ive screening, and so on, may also detect asymptomatic
isease.
amily history and pedigree analysis. A thorough family
istory should be taken on every individual with IDC
101–103). Usually targeted family history questions can be
sed to elicit any obvious family history of DCM or HF.
owever, recording a three-generation pedigree (including
iblings, children, parents, grandparents, aunts and uncles,
nd nieces and nephews of the index patient) is a more
omplete, but time-consuming, approach. Pedigree analysis
nd medical history can provide crucial information but are
nsensitive when used alone. Nevertheless, until genetic
esting is ready for widespread use, clinical screening will
emain the most efficient method for early detection of
DC. Furthermore, a distinction should be made between a
amily history that is negative for cardiovascular disease and
ne that is inconclusive. In the former case, the patient
rovides a clear family history, the family is of relatively
ood size, and no suspicious cardiovascular signs or symp-
oms or history of known cardiovascular disease are present.
n the latter case, the patient may provide a poor or
ncomplete family history, may have information on few or
o family members, and/or the patient or their parents may
e adopted. Even though the latter situations reduce the
alue of family history in a particular case, they do not
ecrease or exclude the possibility of a heritable cardiovas-
ular disease.
The primary goals of pedigree analysis are to diagnose
DC versus FDC and to identify at-risk family members in
rder to recommend that they be screened. In the absence of
nother family member with known IDC, a high level of
Table 1. Clinical and Family Studies to Assess Frequency of Familial Dilated Cardiomyopathy
Author and Year
Location of
Study Patient Population
Method to Identify
Familial Disease
Number of FDC/
Number of IDC (%) Reference
Fuster, 1981 Rochester, MN Consecutive IDC patients diagnosed 1960–1973,
Mayo Clinic
Retrospective chart review of available history 2 of 104 (2%) (8)
Lengyel, 1981 Budapest, Hungary All patients studied with echocardiography and
IDC, 1973–1979, Hungarian Institute of
Cardiology
Not stated 5 of 98 (5%) (24)
Michels, 1985 Rochester, MN Patients 50 yrs with IDC, 1976–1982,
Mayo Clinic
Retrospective chart review, prospective family
history screening questionnaire
11 of 165 (7%) (25)
Pongpanich,
1986
Bangkok, Thailand Consecutive pediatric patients with congestive
cardiomyopathy, 1969–1984, Mahidol
University
Family history of sibling with same condition 5 of 50 (10%) (26)
Fragola, 1988 Rome, Italy 12 of 43 patients with IDC in 1985–1986
consented to participate, none with positive
FH, University of Rome
Prospective echocardiographic screening 4 of 12 (33%) (27)
Griffin, 1988 St. Louis, MO Children diagnosed with IDC 1975–1985,
Washington University
Telephone follow-up; group I 2 yrs of age
at presentation, group II 2 yrs of age at
presentation
Group I: 0 of 20 (0%);
group II: 3 of 12 (25%)
(28)
Valantine, 1989 Stanford, CA All cardiac transplant recipients 1976–1986,
Stanford University
Retrospective history review 11 of 179 (6%) (29)
Keren, 1990 Jerusalem, Israel;
Stanford, CA
Patients with mildly dilated cardiomyopathy,
Hadassah and Stanford universities
Not stated 9 of 16 (56%) (30)
Mestroni, 1990 Trieste, Italy Consecutive patients with IDC, 1979–1988,
University of Trieste
Prospective historical screening 12 of 65 (7%) (31)
Michels, 1992 Rochester, MN Patients with ejection fraction 50% and IDC
identified by medical record review,
1987–1989, Mayo Clinic
Prospective echocardiographic screening of
relatives of patients with IDC
12 of 59 (20%) (32)
Zachara, 1993 Rome, Italy Consecutive patients with diagnosis of IDC Retrospective historical screening for FDC 12 of 105 (11%) (33)
Keeling, 1995 London, England Prospectively identified cases of IDC at St.
Georges Hospital
Prospective echocardiographic screening of
first degree relatives
10 of 40 (25%) (34)
Honda, 1995 Kobe, Japan Patients with IDC 1973–1990 at Kobe
University Hospital
Prospective evaluation of relatives 10 of 117 confirmed (9%),
29 of 117 suspected (25%)
(35)
Goerss, 1995 Rochester, MN 59 IDC patients from 1992 Michels report and
36 new IDC patients, Mayo Clinic
Prospective echocardiographic screening of
relatives of patients with IDC
23 of 95 (24%),
(27 of 95 indeterminate)
(36)
McKenna, 1997 Dublin, Ireland Patients with IDC with family members and
who participated in FDC screening, University
College
Prospective echocardiographic screening of
first degree relatives
14 of 56 (25%) definite,
15 of 56 (27%) possible
(37)
Grünig, 1998 Heidelberg, Germany Consecutive patients with IDC 1988–1994,
University of Heidelberg
Prospective family history and clinical
screening in some (see text)
156 of 445 (35%) (38)
Continued on next page
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April 5, 2005:969–81 Issues in Familial Dilated Cardiomyopathyuspicion should be raised by the occurrence of heart
ransplantation, HF at an early age (60 years), or non-
pecific unexplained sudden death without associated symp-
oms or history consistent with ischemic heart disease in one
r more first or second degree relatives. When the accuracy
f medical and family history is in question, medical records
nd death certificates may be obtained and carefully re-
iewed to establish accurate histories. The logistics of this is
ery time consuming, and a referral to a cardiovascular
enetics specialist or geneticist may be appropriate in cases
here obtaining this documentation is time-prohibitive.
hould the clinician undertake this effort, consent for
ontact is sought via the proband for his or her family
embers, followed by interaction by the clinician and
is/her staff to gain the requisite clinical information.
Despite the importance of family history and pedigree
nalysis in the care of individuals with IDC and FDC, these
lements do not seem to be a routine component of the
ardiovascular evaluation for these individuals. Even when a
amily history is taken in the cardiology clinic setting,
omplexities of incomplete penetrance and variable expres-
ion can easily preclude the diagnosis from those with
imited knowledge of clinical genetics. From a survey of 643
utch cardiologists (104) regarding their experience with
enetic aspects of HCM (a known genetic disease), their
elf-reported genetic knowledge and skills indicated that
1% did not give genetics information to their HCM
atients. Self-reported knowledge about genetics was low,
ut higher for those who had established a working rela-
ionship with a clinical geneticist. It has been proposed that
he collaboration of cardiologists and genetics professionals
ill be most effective to optimize the care of patients with
enetic cardiac disease (104,105).
chocardiographic and electrocardiographic (ECG)
creening. Echocardiography and electrocardiography per-
it safe, sensitive, noninvasive risk assessment. Clinical
creening (exam, echocardiogram, ECG) of relatives of
atients with IDC and FDC is warranted because a signif-
cant proportion of IDC patients have familial disease that
ay not be detected without formal screening, and once
etected may assist in identifying more distant family
embers who are at risk. Also, FDC gene carriers often do
ot manifest symptoms of HF or arrhythmias until late in
he disease process, usually with moderate or severe LVE
nd systolic dysfunction. Perhaps most important, early
etection by clinical screening may lead to earlier treatment
nterventions that may slow disease progression.
We have previously recommended that all first-degree
elatives (including parents) of patients with IDC undergo
chocardiographic and ECG screening regardless of their
amily history (101,103). The recent American College of
ardiology/American Heart Association HF guidelines
ave also suggested that screening family members should
e considered, and that for a highly positive family history
f DCM referral to a cardiovascular genetics center isindicated (102). Despite careful pedigree analysis, it willTa
b
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Table 2. FDC Disease Genes
Gene Protein Function Disease Presentation/Characteristics References
Autosomal Dominant FDC
Dilated Cardiomyopathy
Phenotype
ACTC cardiac actin sarcomeric protein; muscle contraction MMs in 2 unrelated families. Family 1 affected ages 2, 5, and 36 yrs; one
unaffected at 15 yrs. Family 2 had 4 mutation carriers: 2 with IDC (14
and 14 yrs), and 2 borderline affected.
(42)
DES desmin dystrophin-associated glycoprotein complex;
transduces contractile forces
MM, 1 family, 2 affected, 2 unaffected. Other deceased family members
died between 15–37 yrs of HF.
(43)
SGCD -sarcoglycan dystrophin-associated glycoprotein complex;
transduces contractile forces
MM in 1 family, onset of HF/SCD from 14–38 yrs; 2 IDCs with HF at
9 months and 14 yrs.
(44)
MYH7 -myosin heavy chain sarcomeric protein; muscle contraction Ref. (45): MMs in 2 of 20 families. Family 1: age at diagnosis 2–57 yrs,
6 of 19  20 yrs at diagnosis; aggressive disease, HF, SCD. Family 2:
4 with very early onset (at birth, 2 and 11 yrs; 1 SCD at 2 months).
Ref. (46): 2 MMs in 46 pts with IDC (mean age of IDC onset 29
years).
(45,46)
TNNT2 cardiac troponin T sarcomeric protein; muscle contraction Ref. (45): 2 unrelated families, same 3 bp deletion; early-onset DCM (of
14 affected, 2 infants, 3 teens, and 4 in 20s), prominent SCD. Ref.
(48): 1 family, MM in 20; 14 affected, highly variable severity (HF,
death in 2-yr-old, to minor symptoms later). Ref. (47): 1 family, same
3 bp deletion as Ref. (45), highly variable age of onset of HF.
(45,47,48)
TPM1 -tropomyosin sarcomeric protein; muscle contraction MMs, 2 pts with FDC (of 350 unrelated pts with IDC/FDC). Family 1:
onset at 26 yrs with NSVT; subsequent death while awaiting
transplant. Family 2: onset at 3 months, transplanted at 10 years;
mother with IDC.
(49)
TTN titin sarcomere structure/extensible scaffold for
other proteins
1 MM, 1 NM, 2 large families. 1 family with LVE in teens. DCM, HF:
transplant in 3rd–6th decades.
(50)
VCL metavinculin sarcomere structure; intercalated discs 3 bp deletion in a 39-year-old man with IDC; MM, 52-yr-old woman, 2
affected relatives.
(51)
MYBPC myosin-binding protein C sarcomeric protein; muscle contraction MM in 1 of 46 young pts with IDC. (46)
MLP/CSRP3 muscle LIM protein sarcomere stretch sensor/Z discs W4R mutation in 9 German pts (three families) from a cohort of 536
German patients with IDC: 0 of 136 Japanese IDC patients had the
W4R mutation.
(52)
ACTN2 -actinin-2 sarcomere structure; anchor for myofibrillar
actin
MM in proband with DCM, died at 7 yrs; father died of IDC at 42 yrs
(no DNA).
(53)
PLN phospholamban sarcoplasmic reticulum Ca regulator;
inhibits SERCA2 pump
Ref. (54): NM, 1 family (of 20 screened) with aggressive, early-onset
DCM, HF in 3rd decade; 4 of 12 transplanted. Ref. (55): 2 Greek
families with same NM (from 76 unrelated pts screened), with DCM
in 3rd decade in homozyogous NM carriers; variable onset.
(54,55)
ZASP/LBD3 Cypher/LIM binding domain 3 cytoskeletal assembly; involved in targeting
and clustering of membrane proteins
From a cohort of 100 unrelated individuals with DCM (15 with isolated
noncompaction of LV myocardium, or INLVM), mutations identified
in 6 pts, 2 (1 INLVM) FDC and 4 IDC (3 INLVM). Wide range of
age of onset, from infancy to 2nd to 5th decades.
(56)
MYH6 -myosin heavy chain sarcomeric protein; muscle contraction Preliminary report of 3 MMs from 66 FDC families (57)
Continued on next page
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Table 2 Continued
Gene Protein Function Disease Presentation/Characteristics References
Autosomal Dominant FDC
Dilated Cardiomyopathy
Phenotype
ABCC SUR2A regulatory subunit of Kir6.2, an inwardly
rectifying cardiac KATP channel
1 insertion/deletion mutation, 1 MM in 2 of 323 subjects with IDC. Age
at diagnosis 40 and 55 yrs. Both with DCM, HF, ventricular
tachycardia.
(58)
LMNA lamin A/C xinner leaflet, nuclear membrane protein;
confers stability to nuclear membrane;
gene expression
Ref. (59): MMs in 5 of 11 families (39 total affected) with DCM and
CSD. Disease onset mean 38 yrs (range 19–53 yrs) with asymptomatic
ECG changes in rate/rhythm, then progressive sinus/AV node
dysfunction, 1st, 2nd, 3rd degree heart block; 50% had atrial
fibrillation or flutter, 50% required pacemakers; 65% with DCM
(mild LV dysfunction in 12, HF in 13); 6 transplants, 11 SCD; no
MD. Ref. (60): 1 family, 5 affected (4–30 yrs), 3 with MD, mildly
increased CK. Ref. (62): 2 large families with CSD progressive to
DCM, HF, transplant, or SCD. Family 1: 11 affected of 18 MM,
mean disease onset at 43 yrs. Family 2: 12 affected of 14 NM, mean
disease onset at 31 yrs. No MD. Other reports with prominent CSD,
age of onset usually 30–50 yrs, some HF, occasional MD. See Ref.
(63) for CSD summary. Ref. (65) reported 4 MMs after screening 40
FDC and 9 IDC DNAs.
(59–66)
X-linked FDC
DMD dystrophin primary component of dystrophin-associated
glycoprotein complex; transduces
contractile force
Males present at 20–40 yrs and have rapid disease progression; carrier
females may be affected with a milder phenotype. May have skeletal
myopathy. Creatine kinase levels may be increased.
(70,71)
TAZ/G4.5 tafazzin unknown Infantile, lethal dilated cardiomyopathy. (83,85)
Recessive FDC
TNN13 cardiac troponin I sarcomeric protein, muscle contraction One nuclear family, 2 homozygous siblings with DCM, and 1 sibling
and parents who were heterozygous and had normal cardiovascular
evaluations.
(86)
bp  base pair; CSD  conduction system disease; DCM  dilated cardiomyopathy; DNA  deoxyribonucleic acid; FDC  familial dilated cardiomyopathy; HF  heart failure; IDC  idiopathic dilated cardiomyopathy; LV  left
ventricle; LVE  left ventricular enlargement; MD  muscular dystrophy; MM  missense mutation; NM  nonsense mutation; NSVT  non-sustained ventricular tachycardia; pts  patients; SCD  sudden cardiac death.
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ardiac testing, as relatives with cardiovascular abnormalities
who, if found to be affected, would establish the diagnosis
f familial disease) may be asymptomatic. In one study 83%
f relatives thought to have preclinical disease on echocar-
iograms or ECGs were asymptomatic (101). Clinical
creening (echocardiogram and ECG) lead to the diagnosis
f familial disease in 12% to 15% of apparently isolated
negative family history) IDC cases (32,40), demonstrating
ts greater sensitivity versus family history alone. When
-linked FDC is suspected, at-risk second-degree relatives
hould be screened as well.
iagnosis of FDC. The diagnosis of FDC is made with
wo or more IDC diagnoses in closely related family
embers. Echocardiographic diagnosis is most straightfor-
ard for individuals with clear LVE accompanied by sys-
olic dysfunction, who thus meet the diagnostic criteria for
CM; these individuals should undergo a full cardiovascu-
ar evaluation to rule out detectable causes of DCM such as
schemic etiology before being diagnosed with IDC (or
DC). Additional family members of an FDC kindred who
eet diagnostic criteria for IDC can also be given the
iagnosis of FDC.
ther diagnostic considerations for affected status in an
DC family. Perhaps the greatest difficulty that arises in
creening relatives is determining whether subtle echo and
CG findings are significant and represent early signs of
DC. It has been suggested that LVE may be the single
ost useful criterion in identifying those with preclinical
isease (32,39,106), but other criteria (e.g., the presence of
ultiple “minor” echocardiographic and/or ECG abnor-
alities) have also been proposed (19,106). Unlike in some
enetic cardiac diseases (e.g., long QT syndrome), no ECG
bnormalities are specific to FDC. Common findings in-
lude first- or second-degree heart block; atrial, supraven-
ricular, or ventricular arrhythmias; typical or atypical intra-
entricular conduction delays; or loss of anterior or inferior
orces suggestive of infarct patterns. As previously noted,
DC resulting from mutations in lamin A/C (Table 2)
hould be suspected in families with prominent CSD.
ubtle echo findings, especially of ventricular size, are also
ommon, and standardized criteria should be used to assess
V dimensions such as those based on body surface area
107) or the more recent height- and gender-based stan-
ards from the Framingham study (108). In some families,
eviewing medical records on known affected individuals can
rovide a partial profile of the initial presentation and
atural history of the disease in a particular family. How-
ver, because of intrafamilial variability, such retrospective
eview should only increase suspicion of preclinical disease
nd not decrease the suspicion of disease in an individual
hose phenotype differs from that of known affected
ubjects.
TEPWISE SCREENING. If a family member has abnormal
creening results and is suspected to have preclinical or olinical FDC, stepwise screening has been proposed, where
rst-degree relatives of any newly diagnosed individual
ould undergo screening (101). Stepwise screening would
ontinue until first-degree relatives of all individuals with
linical or preclinical FDC have been screened.
erial screening. Because the age of onset varies consider-
bly, normal screening results do not exclude the possibility
f future disease (109). Hence, we have suggested that
dults with normal screening who have a first-degree
elative with FDC should have a repeat echocardiogram and
CG every three to five years (101,109). Those with mild
bnormalities or unexplained symptoms may wish to un-
ergo more frequent screening. It may be reasonable to
ncrease the time interval between screening studies for
lder individuals whose previous studies have been normal.
onsiderations in affected but asymptomatic family
embers. A subset of family members identified to have
symptomatic echocardiographic or ECG abnormalities will
rogress to have symptomatic disease, including DCM, HF,
rrhythmia, and/or sudden death (109). In one study, 27%
f relatives found to have asymptomatic LVE by echocar-
iography progressed to symptomatic DCM over an average
hree-year follow-up period (39). However, early detection
ay enable the treatment and prevention of such problems.
he use of angiotensin-converting enzyme inhibitors to
low disease progression in patients with asymptomatic
DC and left ventricular systolic dysfunction (as observed in
he Studies Of Left Ventricular Dysfunction [SOLVD]
revention trial [110]) may, in a family with FDC, extend to
elatives with asymptomatic LVE and normal systolic func-
ion. Such therapy has been recommended for some indi-
iduals with findings consistent with early disease (101), but
utcomes studies to validate this approach in FDC have not
et been undertaken. Similar salutary effects with beta-
lockers have been observed when treating subjects with
ymptomatic HF from either ischemic or idiopathic DCM
102). Both angiotensin-converting enzyme inhibitors and
eta-blockers are generally well tolerated; therefore, physi-
ians may wish to maintain a low threshold for their use in
amily members with evidence of presymptomatic disease,
specially significant LVE.
ther recommendations. The potential role of lifestyle
odifications for those at risk or with preclinical disease is
nknown. Whether the avoidance of activities such as
ntensive aerobic or strength training may be beneficial is
nknown. These issues have been addressed in the HF
onsensus guidelines (102). Certainly the avoidance of
lcohol and illicit drugs should be encouraged; however, the
ontribution of these environmental factors to the patho-
enesis of disease remains to be established. Because of the
udden cardiac death risk it is appropriate for family
embers to learn cardiopulmonary resuscitation techniques.
creening children. In screening asymptomatic members
f FDC families, clinical disease has been identified in small
hildren and infants. Several of the benefits and limitations
f screening adults extend to children, including the possi-
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April 5, 2005:969–81 Issues in Familial Dilated Cardiomyopathyility for treatment and the unknown significance of some
creening results. Guidelines for the age at which children of
parent with IDC or FDC should be screened have not
een established. Parents should be alert for symptoms of
ardiac disease in at-risk children and should have a low
hreshold for having them evaluated. More aggressive pr-
symptomatic screening is appropriate with disease onset in
hildhood in other family members. Echocardiograms and
CGs on children should be evaluated by centers that can
nterpret pediatric studies.
imitations of recommendations. No expert panel or
onsensus guidelines regarding clinical care for patients or
amilies with FDC have been developed. Further, formal
rospectively designed studies are needed to substantiate the
linical benefit and cost-effectiveness of these screening and
reatment recommendations.
ENETIC COUNSELING AND TESTING FOR FDC
efinition and goals of genetic counseling. Genetic
ounseling is a communication process that includes both
ducational and therapeutic elements targeted to patients
nd their families who face the risk of a genetic disorder
111). The majority of genetic counseling has traditionally
een provided by masters’ trained genetic counselors or
eneticists; however, with greater recognition of genetic
isease in all medical specialties, it will be increasingly
mportant for other health providers to provide some level of
enetic counseling as well.
A genetic counseling session for patients with or at risk
or FDC typically includes 1) a review of the characteristics,
enetics, and inheritance pattern(s) of FDC; 2) a thorough
amily history and pedigree analysis to ascertain the likely
attern of inheritance in the family and identify at-risk
elatives; 3) an explanation of the benefits, risks, and
imitations of clinical and/or genetic testing for affected
ndividuals and their at-risk relatives; and 4) assisting the
amily in making psychosocial adjustments to the recogni-
ion of a potentially heritable disorder in the family
103,112,113).
rovision of genetic counseling for FDC. There are no
stablished guidelines as to when it is appropriate to refer a
atient with IDC/FDC for genetic counseling and, as a
esult, patients with IDC/FDC seldom receive genetic
Table 3. Possible Outcomes of Clinical Screen
If Clinical Screeni
Positive consequences Relief; removal of some
No immediate medical c
not affected
Negative consequences Survivor guilt possible
Uncertainties remaining Possibility of future dise
Question of how often t
Offspring remain at risk*Clinical screening includes a medical and family history, electrocaounseling from any source. As the potential genetic basis
or IDC and FDC becomes more widely recognized by the
ardiovascular community, cardiologists may provide more
nformation regarding the genetics of IDC/FDC to their
atients. Referrals to specialists (e.g., genetic counselors,
eneticists, or cardiovascular specialists recognized as ex-
erts in genetic cardiomyopathies) may also become more
ommon, especially in cases with severe phenotypes or
xtended family histories, or upon patient request. In any
ase, it is imperative for those providing genetic counseling
o have the expertise to deal with the genetic and related
sychosocial issues within the context of appropriate and
p-to-date cardiovascular and genetic diagnosis, manage-
ent, and insight into prognosis.
sychosocial issues in counseling. Family members of
atients with FDC should be counseled about the potential
ositive and negative consequences of screening, including
linical and genetic testing, and the associated uncertainties
Table 3). Many report significant anxiety regarding their
wn risk to develop disease. Undergoing clinical screening
nd following appropriate interventions may alleviate some
nxiety, whether or not screening results are normal. How-
ver, that DCM can present with sudden death creates an
bstacle to alleviation of anxiety for some.
he current state of genetic testing. Genetic testing for
DC is currently not widely available for two reasons. First,
he number of different genes involved in IDC/FDC and
he number of different possible mutations in each of these
enes (i.e., locus and allelic heterogeneity) makes the devel-
pment of a comprehensive genetic test difficult. Second, a
ignificant proportion of FDC cases are not attributable to
ny of the known putative genes, making genetic testing
elatively insensitive. It is expected that genetic testing will
merge with the identification of several additional genes
hat cause or contribute to the FDC phenotype and with
dvances in deoxyribonucleic acid (DNA) testing technol-
gies. Nevertheless, although sensitive, comprehensive ge-
etic testing may not be widely available for several years, it
s prudent to consider the role genetic testing likely will play
n the management of individuals with FDC and their
amilies, as well as key issues related to genetic testing. For
xample, some phenotypes, such as prominent conduction
ystem disease (especially in families requiring pacemakers,
or Familial Dilated Cardiomyopathy*
ormal: If Clinical Screening Abnormal:
tainty Relief; removal of some uncertainty
insurance is
Anxiety, guilt, jealousy, anger
Anticipation of worsening disease
Medical costs; insurability concerns
Offspring are at risk
Significance of screening results
reen How aggressively to follow up
Whether or not to begin treatmenting f
ng N
uncer
osts;
ase
o rescrdiography, and echocardiogram; but not DNA testing.
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pecific etiologies such as lamin cardiomyopathy, for which
esting may soon emerge. The discovery of additional FDC
isease genes will augment genetic counseling by enabling
rospective studies of gene penetrance, genotype-phenotype
orrelations, and the true incidence and prevalence of FDC.
sual indications for genetic testing. Usual indications
or genetic testing include confirmation of a known or
uspected diagnosis, prediction of the possibility of future
llness (presymptomatic testing), detection of the presence
f a carrier state in unaffected individuals (whose children
ay be at risk), and prediction of response to therapy.
ecause not all IDC is due to inherited susceptibility, other
ndividuals who might consider genetic testing include
hose with IDC who have a positive family history, family
embers of individuals with FDC who have an identified
utation, or individuals who have early-onset IDC.
resymptomatic genetic testing. Presymptomatic genetic
esting is testing performed on asymptomatic individuals
ho are at-risk for a particular genetic condition. The
iscovery of a gene mutation in such individuals indicates a
eightened risk of development of findings related to the
ondition at some future point. Such testing must begin
ith an affected family member in order for the testing to be
nformative. If a putative causative mutation is identified in
n affected individual, only then is it possible to offer
nformative testing to at-risk relatives; otherwise, the pur-
orted cause of FDC in the family has not been identified,
nd a negative test result may not reduce that individual’s
isk of FDC.
enefits of genetic testing. CONFIRMATION OF DIAGNOSIS.
enetic testing is often used to facilitate the confirmation of
clinical diagnosis. Although the criteria to establish a
iagnosis of IDC are straightforward, establishing a diag-
osis of FDC is more difficult and in cases of negative or
nconclusive family history, genetic testing may be the only
ay to confirm FDC.
ARLY DETECTION AND PREVENTION. The possibility of
rophylactic intervention for those confirmed to be muta-
ion carriers exists; however, the efficacy of such treatments
emains uncertain. Clinical screening (albeit more vigilant)
ill remain the cornerstone of monitoring for disease
resentation in mutation-positive individuals. It is for these
easons that genetic testing remains a case-by-case, individ-
al decision.
XCLUSION OF A CAUSATIVE MUTATION. In a family with a
nown mutation causative of FDC, excluding the mutation
n an at-risk family member can be extremely beneficial.
eriodic clinical screening would not be required and
oncerns regarding reproductive choices can be addressed.
imitations of genetic testing. Genetic testing can pro-
ide only limited information about an inherited condition.
uch testing cannot determine whether a person will show
ymptoms of a disorder, the severity of the symptoms, or its
atural history. Although some prophylactic treatmenteasures may improve outcomes for individuals at risk for
DC, they have not been proven, and for some individuals
here will be a lack of treatment strategies. Also, testing is
imited by the sensitivity to detect genetic causation.
nformed consent process. Many commercial DNA lab-
ratories require written documentation by a specialist
efore accepting DNA samples for presymptomatic genetic
esting.
linical versus research genetic testing. Clinical genetic
esting is performed by a laboratory subject to regulation by
he federal Clinical Laboratories Improvement Act (CLIA),
law passed by Congress in 1988. Most research laborato-
ies are not CLIA-certified and are therefore unable to
rovide clinical genetic results. Clinical and research genetic
esting options are listed in a continuously updated database
t the GeneTests/GeneClinics website (114).
enetic counseling in the absence of genetic testing. For
ome genetic conditions, the demand for genetic counseling
ervices has been driven by availability of genetic testing.
or example, even though genetic counseling for individuals
t-risk for breast and ovarian cancer was performed before
he widespread availability of BRCA1 and BRCA2 testing,
he demand for genetic counseling services increased signif-
cantly with the advent of the genetic tests (115). It seems
ogical that the same pattern would emerge once genetic
esting for FDC becomes available.
Facilitating decisions about genetic testing is, however,
nly one aspect of genetic counseling. Counseling can be
eneficial for patients with FDC and their family members
or several other reasons. First, early detection and treat-
ent of DCM is beneficial. Dilated cardiomyopathy causes
ubstantial morbidity and mortality and treatment of ad-
anced disease is costly, justifying measures to prevent or
meliorate it in its initial stages through the identification
nd clinical screening of at-risk individuals. Second, cardi-
logists often do not recognize FDC in their practices;
mong those who do, it is likely that few provide accurate
isk assessment, genetic education, and screening recom-
endations. Third, with a diagnosis of FDC a host of
ifficult psychological, social, and ethical issues unique to
enetic disease emerge, which often cannot be addressed in
routine cardiology clinic visit.
eprint requests and correspondence: Dr. Ray E. Hershberger,
ivision of Cardiology, UHN-62, Oregon Health and Science
niversity, 3181 SW Sam Jackson Park Road, Portland, Oregon
7239. E-mail: hershber@ohsu.edu, or www.fdc.to.
EFERENCES
1. Seidman C, Seidman J. Molecular genetic studies of familial hyper-
trophic cardiomyopathy. Basic Res Cardiol 1998;93 Suppl 3:13–6.
2. Priori SG. Inherited arrhythmogenic diseases: the complexity beyond
monogenic disorders. Circ Res 2004;94:140–5.
3. Ahmad F. The molecular genetics of arrhythmogenic right ventric-
ular dysplasia-cardiomyopathy. Clin Invest Med 2003;26:167–78.4. Maron B, Moller J, Seidman C, et al. Impact of laboratory molectular
diagnosis on contemporary diagnostic criteria for genetically trans-
979JACC Vol. 45, No. 7, 2005 Burkett and Hershberger
April 5, 2005:969–81 Issues in Familial Dilated Cardiomyopathymitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT
syndrome, and Marfan syndrome. Circulation 1998;98:1460–71.
5. Cripe L, Andelfinger G, Martin LJ, Shooner K, Benson DW. Bicuspid
aortic valve is heritable. J Am Coll Cardiol 2004;44:138–43.
6. Darbar D, Herron KJ, Ballew JD, et al. Familial atrial fibrillation is
a genetically heterogeneous disorder. J Am Coll Cardiol 2003;41:
2185–92.
7. Fox CS, Parise H, D’Agostino RB, Sr., et al. Parental atrial
fibrillation as a risk factor for atrial fibrillation in offspring. JAMA
2004;291:2851–5.
8. Fuster B, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye
RL. The natural history of idiopathic dilated cardiomyopathy. Am J
Cardiol 1981;47:525–31.
9. Johnson RA, Palacios I. Dilated cardiomyopathies of the adult.
N Engl J Med 1982;307:1051–8.
10. Abelmann W. Classification and natural history of primary myocar-
dial disease. Prog Cardiovasc Dis 1984;27:73–94.
11. Caforio A, Stewart J, McKenna W. Idiopathic dilated cardiomyop-
athy. BMJ 1990;300:890–1.
12. Sui S, Sole M. Dilated cardiomyopathy. Curr Opin Cardiol 1994;9:
337–43.
13. Dec G, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med
1994;331:1564–75.
14. McMinn T, Ross J, Jr. Hereditary dilated cardiomyopathy. Clin
Cardiol 1995;18:7–15.
15. Schowengerdt K, Towbin J. Genetic basis of inherited cardiomyop-
athies. Curr Opin Cardiol 1995;10:312–21.
16. Michels VV. Progress in defining the causes of idiopathic dilated
cardiomyopathy. N Engl J Med 1993;329:960–1.
17. Mestroni L, Giacca M. Molecular genetics of dilated cardiomyopa-
thy. Curr Opin Cardiol 1997;12:303–9.
18. Cox G, Kunkel L. Dystrophies and heart disease. Curr Opin Cardiol
1997;12:329–43.
19. Mestroni L, Maisch B, McKenna W, et al. Guidelines for the study
of familial dilated cardiomyopathies. Eur Heart J 1999;20:93–102.
20. Arbustini E, Morbini P, Pilotto A, Gavazzi A, Tavazzi L. Familial
dilated cardiomyopathy: from clinical presentation to molecular
genetics. Eur Heart J 2000;21:1825–32.
21. Schonberger J, Seidman CE. Many roads lead to a broken heart: the
genetics of dilated cardiomyopathy. Am J HumGenet 2001;69:249–60.
22. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from
mutation identification to mechanistic paradigms. Cell 2001;104:
557–67.
23. Towbin JA, Bowles NE. The failing heart. Nature 2002;415:227–33.
24. Lengyel M, Kökeny M. Follow-up study in congestive (dilated)
cardiomyopathy. Acta Cardiologica 1981;36:35–48.
25. Michels VV, Driscoll DJ, Miller FA. Familial aggregation of idio-
pathic dilated cardiomyopathy. Am J Cardiol 1985;55:1232–3.
26. Pongpanich B, Isaraprasart S. Congestive cardiomyopathy in infants
and children. Jpn Heart J 1986;27:11–5.
27. Fragola PV, Autore C, Picelli A, Sommariva L, Cannata D,
Sangiorgi M. Familial idiopathic dilated cardiomyopathy. Am
Heart J 1988;115:912–4.
28. Griffin M, Hernandez A, Martin T, et al. Dilated cardiomyopathy in
infants and children. J Am Coll Cardiol 1988;11:139–44.
29. Valantine HA, Hunt SA, Fowler MB, Billingham ME, Schroeder
JS. Frequency of familial nature of dilated cardiomyopathy and
usefulness of cardiac transplantation in this subset. Am J Cardiol
1989;63:959–63.
30. Keren A, Gottlief S, Tzivoni D, et al. Mildly dilated congestive
cardiomyopathy. Circulation 1990;81:506–17.
31. Mestroni L, Miani D, Di Lenarda A, et al. Clinical and pathologic
study of familial dilated cardiomyopathy. Am J Cardiol 1990;65:
1449–53.
32. Michels VV, Moll PP, Miller FA, et al. The frequency of familial
dilated cardiomyopathy in a series of patients with idiopathic dilated
cardiomyopathy. N Engl J Med 1992;326:77–82.
33. Zachara E, Caforio ALP, Carboni GP, et al. Familial aggregation of
idiopathic dilated cardiomyopathy: clinical features and pedigree
analysis in 14 families. Br Heart J 1993;69:129–35.
34. Keeling P, Gang Y, Smith G, et al. Familial dilated cardiomyopathy
in the United Kingdom. Br Heart J 1995;73:417–21.35. Honda Y, Yokota Y, Yokoyama M. Familial aggregation of dilated
cardiomyopathy. Evaluation of clinical characteristics and prognosis.
Jpn Circ J 1995;59:589–98.
36. Goerss J, Michels V, Burnett J, et al. Frequency of familial dilated
cardiomyopathy. Eur Heart J 1995;16 Suppl O:2–4.
37. McKenna C, Codd M, McCann H, Sugrue D. Idiopathic dilated
cardiomyopathy: familial prevalence and HLA distribution. Heart
1997;77:549–52.
38. Grünig E, Tasman JA, Kücherer H, Franz W, Kubler W, Katus HA.
Frequency and phenotypes of familial dilated cardiomyopathy. J Am
Coll Cardiol 1998;31:186–94.
39. Baig MK, Goldman JH, Caforio AP, Coonar AS, Keeling PJ,
McKenna WJ. Familial dilated cardiomyopathy: cardiac abnormali-
ties are common in asymptomatic relatives and may represent early
disease. J Am Coll Cardiol 1998;31:195–201.
40. Mestroni L, Rocco C, Gregori D, et al. Familial dilated cardiomy-
opathy: evidence for genetic and phenotypic heterogeneity. J Am Coll
Cardiol 1999;34:181–90.
41. Michels VV, Driscoll DJ, Miller FA, et al. Progression of familial and
non-familial dilated cardiomyopathy: long term follow up. Heart
2003;89:757–61.
42. Olson TM,Michels VV, Thibodeau SN, Tai YS, Keating MT. Actin
mutations in dilated cardiomyopathy, a heritable form of heart
failure. Science 1998;280:750–2.
43. Li D, Tapscoft T, Gonzalez O, et al. Desmin mutation responsible
for idiopathic dilated cardiomyopathy. Circulation 1999;100:461–4.
44. Tsubata S, Bowles KR, Vatta M, et al. Mutations in the human
delta-sarcoglycan gene in familial and sporadic dilated cardiomyop-
athy. J Clin Invest 2000;106:655–62.
45. Kamisago M, Sharma SD, DePalma SR, et al. Mutations in
sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl
J Med 2000;343:1688–96.
46. Daehmlow S, Erdmann J, Knueppel T, et al. Novel mutations in
sarcomeric protein genes in dilated cardiomyopathy. Biochem Bio-
phys Res Commun 2002;298:116–20.
47. Li D, Czernuszewicz GZ, Gonzalez O, et al. Novel cardiac troponin
T mutation as a cause of familial dilated cardiomyopathy. Circulation
2001;104:2188–93.
48. Hanson E, Jakobs P, Keegan H, et al. Cardiac troponin T lysine-210
deletion in a family with dilated cardiomyopathy. J Card Fail
2002;8:28–32.
49. Olson TM, Kishimoto NY, Whitby FG, Michels VV. Mutations
that alter the surface charge of alpha-tropomyosin are associated with
dilated cardiomyopathy. J Mol Cell Cardiol 2001;33:723–32.
50. Gerull B, Gramlich M, Atherton J, et al. Mutations of TTN,
encoding the giant muscle filament titin, cause familial dilated
cardiomyopathy. Nat Genet 2002;14:14.
51. Olson TM, Illenberger S, Kishimoto NY, Huttelmaier S, Keating
MT, Jockusch BM. Metavinculin mutations alter actin interaction in
dilated cardiomyopathy. Circulation 2002;105:431–7.
52. Knoll R, Hoshijima M, Hoffman HM, et al. The cardiac mechanical
stretch sensor machinery involves a Z disc complex that is defective in
a subset of human dilated cardiomyopathy. Cell 2002;111:943–55.
53. Mohapatra B, Jimenez S, Lin JH, et al. Mutations in the muscle LIM
protein and alpha-actinin-2 genes in dilated cardiomyopathy and
endocardial fibroelastosis. Mol Genet Metab 2003;80:207–15.
54. Schmitt JP, Kamisago M, Asahi M, et al. Dilated cardiomyopathy
and heart failure caused by a mutation in phospholamban. Science
2003;299:1410–3.
55. Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null
results in lethal dilated cardiomyopathy revealing a critical difference
between mouse and human. J Clin Invest 2003;111:869–76.
56. Vatta M, Mohapatra B, Jimenez S, et al. Mutations in Cypher/ZASP
in patients with dilated cardiomyopathy and left ventricular non-
compaction. J Am Coll Cardiol 2003;42:2014–27.
57. Carniel E, Taylor MR, Fain P, et al. Molecular screening of
-myosin heavy chain in patients with dilated and hypertrophic
cardiomyopathy. Circulation 2003;108:IV263.
58. Bienengraeber M, Olson TM, Selivanov VA, et al. ABCC9 muta-
tions identified in human dilated cardiomyopathy disrupt catalytic
KATP channel gating. Nat Genet 2004;36:382–7.
59. Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod
domain of the lamin A/C gene as causes of dilated cardiomyopathy
and conduction-system disease. N Engl J Med 1999;341:1715–24.
11
1
1
1
980 Burkett and Hershberger JACC Vol. 45, No. 7, 2005
Issues in Familial Dilated Cardiomyopathy April 5, 2005:969–8160. Brodsky G, Muntoni F, Miocic S, Sinagra G, Sewry C, Mestroni L.
Lamin A/C gene mutation associated with dilated cardiomyopathy
with variable skeletal muscle involvement. Circulation 2000;101:
473–6.
61. Becane HM, Bonne G, Varnous S, et al. High incidence of sudden
death with conduction system and myocardial disease due to lamins
A and C gene mutation. Pacing Clin Electrophysiol 2000;23:1661–6.
62. Jakobs PM, Hanson E, Crispell KA, et al. Novel lamin A/C
mutations in two families with dilated cardiomyopathy and conduc-
tion system disease. J Card Fail 2001;7:249–56.
63. Hershberger RE, Hanson E, Jakobs PM, et al. A novel lamin A/C
mutation in a family with dilated cardiomyopathy, prominent con-
duction system disease, and need for permanent pacemaker implan-
tation. Am Heart J 2002;144:1081–6.
64. Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated
cardiomyopathy with atrioventricular block: a lamin A/C defect-
related disease. J Am Coll Cardiol 2002;39:981–90.
65. Taylor MR, Fain PR, Sinagra G, et al. Natural history of dilated
cardiomyopathy due to lamin A/C gene mutations. J Am Coll
Cardiol 2003;41:771–80.
66. Sebillon P, Bouchier C, Bidot LD, et al. Expanding the phenotype of
LMNA mutations in dilated cardiomyopathy and functional conse-
quences of these mutations. J Med Genet 2003;40:560–7.
67. Mayosa B, Khogali S, Zhang B, Watkins H. Cardiac and skeletal
actin gene mutations are not a common cause of dilated cardiomy-
opathy. J Med Genet 1999;36:796–7.
68. Takai E, Akita H, Shiga N, et al. Mutational analysis of the cardiac
actin gene in familial and sporadic dilated cardiomyopathy. Am J
Med Genet 1999;86:325–7.
69. Tesson F, Sylvius N, Pilotto A, et al. Epidemiology of desmin and
cardiac actin gene mutations in a European population of dilated
cardiomyopathy. Eur Heart J 2000;21:1872–6.
70. Muntoni F, Cau M, Ganau A, et al. Brief report: Deletion of the
dystrophin muscle-promoter region associated with X-linked dilated
cardiomyopathy. N Engl J Med 1993;329:921–5.
71. Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardio-
myopathy. Molecular genetic evidence of linkage to the Duchenne
muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation
1993;87:1854–65.
72. Milasin J, Muntoni F, Severini GM, et al. A point mutation in the
5= splice site of the dystrophin gene first intron responsible for
X-linked dilated cardiomyopathy. Hum Mol Genet 1996;5:73–9.
73. Bies R, Maeda M, Roberds S, et al. A 5= dystrophin duplication
mutation causes membrane deficiency of -dystroglycan in a family with
X-linked cardiomyopathy. J Mol Cell Cardiol 1997;29:3175–88.
74. Muntoni F, Di Lenarda A, Porcu M, et al. Dystrophin gene
abnormalities in two patients with idiopathic dilated cardiomyopathy.
Heart 1997;78:608–12.
75. Ortiz-Lopez R, Li H, Su J, Goythia V, Towbin J. Evidence for a
dystrophin missense mutation as a cause of X-linked dilated cardio-
myopathy. Circulation 1997;95:2434–40.
76. Ferlini A, Galie N, Merlini L, Sewry C, Branzi A, Muntoni F. A
novel Alu-like element rearranged in the dystrophin gene causes a
splicing mutation in a family with X-linked dilated cardiomyopathy.
Am J Hum Genet 1998;63:436–46.
77. Yoshida K, Nakamura A, Yazaki M, Ikeda S, Takeda S. Insertional
mutation by transposable element, L1, in the DMD gene results in
X-linked dilated cardiomyopathy. HumMol Genet 1998;7:1129–32.
78. Franz WM, Muller M, Muller OJ, et al. Association of nonsense
mutation of dystrophin gene with disruption of sarcoglycan complex
in X-linked dilated cardiomyopathy. Lancet 2000;355:1781–5.
79. Politano L, Nigro V, Nigro G, et al. Development of cardiomyopathy
in female carriers of Duchenne and Becker muscular dystrophies.
JAMA 1996;275:1335–8.
80. Hoogerwaard EM, Bakker E, Ippel PF, et al. Signs and symptoms of
Duchenne muscular dystrophy and Becker muscular dystrophy
among carriers in the Netherlands: a cohort study. Lancet 1999;353:
2116–9.
81. Palmucci L, Mongini T, Chiado-Piat L, Doriguzzi C, Fubini A.
Dystrophinopathy expressing as either cardiomyopathy or Becker
dystrophy in the same family. Neurology 2000;54:529–30.
82. Muntoni F, DiLenarda A, Porcu M, et al. Dystrophin gene abnor-
malities in two patients with idiopathic dilated cardiomyopathy.
Heart 1997;78:608–12.
183. Bione S, D’Adamo P, Maestrini E, Gedeon A, Bolhuis P, Toniolo
D. A novel X-linked gene, G4.5, is responsible for Barth syndrome.
Nat Genet 1996;12:385–9.
84. Bleyl SB, Mumford BR, Thompson V, et al. Neonatal, lethal
noncompaction of the left ventricular myocardium is allelic with
Barth syndrome. Am J Hum Genet 1997;61:868–72.
85. D’Adamo P, Fassone L, Gedeon A, et al. The X-linked gene G4.5 is
responsible for different infantile dilated cardiomyopathies. Am J
Hum Genet 1997;61:862–7.
86. Murphy RT, Mogensen J, Shaw A, Kubo T, Hughes S, McKenna
WJ. Novel mutation in cardiac troponin I in recessive idiopathic
dilated cardiomyopathy. Lancet 2004;363:371–2.
87. Seliem MA, Mansara KB, Palileo M, Ye X, Zhang Z, Benson DW.
Evidence for autosomal recessive inheritance of infantile dilated
cardiomyopathy: studies from the Eastern Province of Saudi Arabia.
Pediatr Res 2000;48:770–5.
88. Messina DN, Speer MC, Pericak-Vance MA, McNally EM. Link-
age of familial dilated cardiomyopathy with conduction defect and
muscular dystrophy to chromosome 6q23. Am J Human Genet
1997;61:909–7.
89. Arbustini E, Diegoli M, Fasani R, et al. Mitochondrial DNA
mutations and mitochondrial abnormalities in dilated cardiomyopa-
thy. Am J Pathol 1998;153:1501–10.
90. Li YY, Maisch B, Rose ML, Hengstenberg C. Point mutations in
mitochondrial DNA of patients with dilated cardiomyopathy. J Mol
Cell Cardiol 1997;29:2699–709.
91. Marin-Garcia J, Goldenthal MJ, Ananthakrishnan R, et al. Specific
mitochondrial DNA deletions in idiopathic dilated cardiomyopathy.
Cardiovasc Res 1996;31:306–13.
92. Remes AM, Hassinen IE, Ikaheimo MJ, Herva R, Hirvonen J,
Peuhkurinen KJ. Mitochondrial DNA deletions in dilated cardiomy-
opathy: a clinical study employing endomyocardial sampling. J Am
Coll Cardiol 1994;23:935–42.
93. Silvestri G, Santorelli FM, Shanske S, et al. A new mtDNAmutation
in the tRNA(Leu[UUR]) gene associated with maternally inherited
cardiomyopathy. Hum Mutat 1994;3:37–43.
94. Suomalainen A, Paetau A, Leinonen H, Majander A, Peltonen L,
Somer H. Inherited idiopathic dilated cardiomyopathy with multiple
deletions of mitochondrial DNA. Lancet 1992;340:1319–20.
95. Krajinovic M, Pinamonti B, Sinagra G, et al. Linkage of familial
dilated cardiomyopathy to chromosome 9. Am J Hum Genet
1995;57:846–52.
96. Bowles KR, Gajarski R, Porter P, et al. Gene mapping of familial
autosomal dominant dilated cardiomyopathy to chromosome 10q21-
23. J Clin Invest 1996;96:1355–60.
97. Schönberger J, Levy H, Grünig E, et al. Dilated cardiomyopathy and
sensorineural hearing loss: a heritable syndrome that maps to 6q23-
24. Circulation 2000;101:1812–8.
98. Sylvius N, Tesson F, Gayet C, et al. A new locus for autosomal
dominant dilated cardiomyopathy identified on chromosome 6q12-
q16. Am J Hum Genet 2001;68:241–6.
99. Olson TM, Keating MT. Mapping a cardiomyopathy locus to
chromosome 3p22-p25. J Clin Invest 1996;97:528–32.
00. Jung M, Poepping I, Perrot A, et al. Investigation of a family with
autosomal dominant dilated cardiomyopathy defines a novel locus on
chromosome 2q14-q22. Am J Hum Genet 1999;65:1068–77.
01. Crispell K, Wray A, Ni H, Nauman D, Hershberger R. Clinical
profiles of four large pedigrees with familial dilated cardiomyopathy:
preliminary recommendations for clinical practice. J Am Coll Cardiol
1999;34:837–47.
02. Hunt S, Baker D, Chin M, et al. ACC/AHA guidelines for the
evaluation and management of chronic heart failure in the adult: a
report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines. Available at: http://
www.acc.org/clinical/guidelines/failure/hf_index.htm. 2001. Ac-
cessed June 30, 2004.
03. Hanson E, Hershberger RE. Genetic counseling and screening issues
in familial dilated cardiomyopathy. J Genet Counseling 2001;10:397–
415.
04. van Langen IM, Birnie E, Leschot NJ, Bonsel GJ, Wilde AA.
Genetic knowledge and counselling skills of Dutch cardiologists:
sufficient for the genomics era? Eur Heart J 2003;24:560–6.05. Yu B, French JA, Jeremy RW, et al. Counselling issues in familial
hypertrophic cardiomyopathy. J Med Genet 1998;35:183–8.
11
1
1
1
1
1
1
1
1
981JACC Vol. 45, No. 7, 2005 Burkett and Hershberger
April 5, 2005:969–81 Issues in Familial Dilated Cardiomyopathy06. Hershberger RE, Ni H, Crispell KA. Familial dilated cardiomyop-
athy: echocardiographic diagnostic criteria for classification of family
members as affected. J Cardiac Fail 1999;51:203–12.
07. Henry W, Gardin J, Ware J. Echocardiographic measurements in
normal subjects from infancy to old age. Circulation 1980;62:1054–61.
08. Vasan R, Larson M, Levy D, Evans J, Benjamin E. Distribution and
categorization of echocardiographic measurements in relation to
reference limits. The Framingham Heart Study: formulation of a
height- and sex-specific classification and its prospective validation.
Circulation 1997;96:1863–73.
09. Crispell KA, Hanson E, Coates K, Toy W, Hershberger R. Periodic
rescreening is indicated for family members at risk of developing
familial dilated cardiomyopathy. J Am Coll Cardiol 2002;39:1503–7.10. The SOLVD Investigators. Effect of enalapril on mortality and the
development of heart failure in asymptomatic patients with reduced
left ventricular ejection fractions. N Engl J Med 1992;327:685–91.
11. Biesecker BB. Goals of genetic counseling. Clin Genet 2001;60:
323–30.
12. Baker DL, Schuette JL, Uhlmann WR. A Guide to Genetic
Counseling. New York, NY: Wiley-Liss, 1998.
13. Fraser FC. Genetic counseling. Am J Hum Genet 1974;26:636–61.
14. GeneTests/GeneClinics. Available at: www.geneclinics.org. Ac-
cessed June 30, 2004.
15. Hartenbach EM, Becker JM, Grosen EA, et al. Progress of a
comprehensive familial cancer genetic counseling program in the era
of BRCA1 and BRCA2. Genet Test 2002;6:75–8.
